Recently, T-Dxd was approved for patients with HER2-positive unresectable or metastatic BC, who received at least two prior anti-HER2-directed treatments, based on the results of the DESTINY-Breast01 trial [8] (Table 1). The gene discussed is ERBB2; the disease is breast cancer.